TY - JOUR
T1 - Type I and III IFNs produced by the nasal epithelia and dimmed inflammation are features of alpacas resolving MERS-CoV infection
AU - Te, Nigeer
AU - Rodon, Jordi
AU - Ballester, Maria
AU - Pérez, Mónica
AU - Pailler-García, Lola
AU - Segalés, Joaquim
AU - Vergara-Alert, Júlia
AU - Bensaid, Albert
A2 - Perlman, Stanley
N1 - Publisher Copyright:
© 2021 Te et al.
PY - 2021/5/24
Y1 - 2021/5/24
N2 - While MERS-CoV (Middle East respiratory syndrome Coronavirus) provokes a lethal disease in humans, camelids, the main virus reservoir, are asymptomatic carriers, suggesting a crucial role for innate immune responses in controlling the infection. Experimentally infected camelids clear infectious virus within one week and mount an effective adaptive immune response. Here, transcription of immune response genes was monitored in the respiratory tract of MERS-CoV infected alpacas. Concomitant to the peak of infection, occurring at 2 days post inoculation (dpi), type I and III interferons (IFNs) were maximally transcribed only in the nasal mucosa of alpacas, while interferon stimulated genes (ISGs) were induced along the whole respiratory tract. Simultaneous to mild focal infiltration of leukocytes in nasal mucosa and submucosa, upregulation of the anti-inflammatory cytokine IL10 and dampened transcription of pro-inflammatory genes under NF-κB control were observed. In the lung, early (1 dpi) transcription of chemokines (CCL2 and CCL3) correlated with a transient accumulation of mainly mononuclear leukocytes. A tight regulation of IFNs in lungs with expression of ISGs and controlled inflammatory responses, might contribute to virus clearance without causing tissue damage. Thus, the nasal mucosa, the main target of MERS-CoV in camelids, seems central in driving an efficient innate immune response based on triggering ISGs as well as the dual anti-inflammatory effects of type III IFNs and IL10.
AB - While MERS-CoV (Middle East respiratory syndrome Coronavirus) provokes a lethal disease in humans, camelids, the main virus reservoir, are asymptomatic carriers, suggesting a crucial role for innate immune responses in controlling the infection. Experimentally infected camelids clear infectious virus within one week and mount an effective adaptive immune response. Here, transcription of immune response genes was monitored in the respiratory tract of MERS-CoV infected alpacas. Concomitant to the peak of infection, occurring at 2 days post inoculation (dpi), type I and III interferons (IFNs) were maximally transcribed only in the nasal mucosa of alpacas, while interferon stimulated genes (ISGs) were induced along the whole respiratory tract. Simultaneous to mild focal infiltration of leukocytes in nasal mucosa and submucosa, upregulation of the anti-inflammatory cytokine IL10 and dampened transcription of pro-inflammatory genes under NF-κB control were observed. In the lung, early (1 dpi) transcription of chemokines (CCL2 and CCL3) correlated with a transient accumulation of mainly mononuclear leukocytes. A tight regulation of IFNs in lungs with expression of ISGs and controlled inflammatory responses, might contribute to virus clearance without causing tissue damage. Thus, the nasal mucosa, the main target of MERS-CoV in camelids, seems central in driving an efficient innate immune response based on triggering ISGs as well as the dual anti-inflammatory effects of type III IFNs and IL10.
KW - Animals
KW - Antiviral Agents/metabolism
KW - Camelids, New World/immunology
KW - Chlorocebus aethiops
KW - Coronavirus Infections/immunology
KW - Disease Reservoirs/veterinary
KW - Disease Resistance/drug effects
KW - Gene Expression Regulation
KW - Immunity, Innate/physiology
KW - Inflammation/immunology
KW - Interferon Type I/genetics
KW - Interferons/genetics
KW - Middle East Respiratory Syndrome Coronavirus/drug effects
KW - Nasal Mucosa/drug effects
KW - Respiratory System/drug effects
KW - Vero Cells
KW - Viral Load/drug effects
KW - Virus Replication/drug effects
UR - https://doi.org/10.1371/journal.ppat.1009229
UR - https://www.scopus.com/pages/publications/85107073993
UR - https://www.mendeley.com/catalogue/a2dd9870-8419-3e66-b818-839f9c92b236/
U2 - 10.1371/journal.ppat.1009229
DO - 10.1371/journal.ppat.1009229
M3 - Article
C2 - 34029358
SN - 1553-7366
VL - 17
JO - PLoS Pathogens
JF - PLoS Pathogens
IS - 5
M1 - e1009229
ER -